Rezdiffra (Resmetirom) Pediatric Titration Schedule: What Women and Families Need to Know

Why Pediatric Resmetirom Matters, Especially for Girls

Metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) is no longer an adult-only disease. Pediatric MASH is rising in parallel with childhood obesity, and adolescent girls carry a disproportionate burden linked to polycystic ovary syndrome and insulin resistance. Understanding where resmetirom stands for younger patients, and what a future titration schedule may look like, matters to mothers, teen girls, and the clinicians caring for them.

Resmetirom is a selective thyroid hormone receptor-beta (THR-beta) agonist. It works by activating THR-beta in liver cells, boosting hepatic fat oxidation and lowering LDL cholesterol, without the cardiac and bone side effects of activating THR-alpha. The MAESTRO-NASH trial showed that 26.1% of patients taking 100 mg reached the primary endpoint of MASH resolution without worsening fibrosis at 52 weeks, compared with 9.7% on placebo, a statistically significant difference that drove FDA approval in March 2024.

That approval, however, covers adults only. No pediatric dosing protocol has been cleared by the FDA as of January 2025.

What "No Pediatric Approval" Actually Means in Practice

It means resmetirom cannot be prescribed on-label to anyone under 18. Clinicians who prescribe it off-label to minors do so without regulatory dosing guidance, without published pediatric pharmacokinetic data, and without pediatric safety data from controlled trials. This is not a technicality. Hepatic enzyme systems, body composition, hormonal milieu, and THR-beta receptor expression all differ between children and adults, and those differences change how a drug distributes, metabolizes, and acts.

For girls specifically, puberty introduces estrogen and progesterone cycling that alters hepatic CYP enzyme activity. Estrogen is known to modulate lipid metabolism in the liver, and THR-beta agonism overlaps with some of those pathways. How resmetirom interacts with the hormonal shifts of puberty has not been studied in any published trial.

The Approved Adult Titration Schedule (The Baseline to Understand)

Before discussing what pediatric titration might look like, you need to understand the adult protocol, because any future pediatric schedule will likely borrow its logic.

Adult Dosing Per FDA Label

The FDA-approved prescribing information for Rezdiffra specifies a weight-based, flat-start dosing approach:

• Body weight <100 kg: 80 mg once daily with food
• Body weight ≥100 kg: 100 mg once daily with food

There is no titration ramp in the adult label. You start at your target dose. This is a meaningful design choice: the MAESTRO-NASH trial enrolled patients at fixed doses from day one, not a step-up schedule. Tolerability data from that trial showed the most common adverse events (diarrhea, nausea) appeared early and were generally mild-to-moderate in severity.

Why No Ramp-Up Is Used in Adults

Most drugs with gastrointestinal side effects use a slow titration to reduce early tolerability issues. Resmetirom's trial design skipped that approach because preclinical and Phase 2 data suggested the GI effects were transient, peaking in the first few weeks and resolving without dose reduction. In the MAESTRO-NASH trial, diarrhea occurred in 32.6% of patients on 100 mg versus 17.0% on placebo, and most cases resolved by week 4 without intervention.

Whether that tolerance-building timeline holds for children, whose gut motility and microbiome differ, is unknown.

Dose Adjustments for Hepatic Impairment

The FDA label restricts use in patients with moderate or severe hepatic impairment (Child-Pugh B or C) because resmetirom is itself metabolized by the liver. Pharmacokinetic modeling showed significantly elevated exposure in moderate impairment. This matters for pediatric MASH patients, some of whom may already have significant fibrosis at diagnosis.

Pediatric MASH: Who Are the Girls Most Affected?

Pediatric MASH does not affect all children equally, and understanding the female-specific risk profile is the foundation of responsible clinical thinking about future resmetirom use.

Adolescent Girls With PCOS

PCOS affects an estimated 8-13% of reproductive-age women globally, and its metabolic features, including hyperinsulinemia, visceral adiposity, and dyslipidemia, are strong drivers of hepatic steatosis. Adolescent girls with PCOS have significantly higher rates of NAFLD compared to age-matched peers without PCOS. A 2019 analysis in Fertility and Sterility found that PCOS was associated with a 2.5-fold increased odds of NAFLD independent of BMI. If resmetirom eventually reaches this population, PCOS status will need to be factored into both the indication and hormone-drug interaction considerations.

Girls With Obesity and Insulin Resistance

Obesity-related MASH in children skews male in prepubertal years, but that gap narrows and may reverse in adolescence as female hormones shift fat distribution toward the visceral compartment. Insulin resistance, the central driver of hepatic fat accumulation, accelerates in puberty for girls who are overweight. This metabolic window, roughly ages 11-16, is exactly when a future pharmacologic option would be considered, and it is also the window where hormonal variability is highest.

Postpubertal vs. Prepubertal Considerations

THR-beta receptors are expressed in liver, but they are also present in the pituitary, where they regulate TSH secretion. In adults, resmetirom at therapeutic doses produces modest reductions in TSH and thyroid hormone levels, effects considered clinically acceptable in adults. In prepubertal children, where the hypothalamic-pituitary-thyroid axis is still establishing its set point, those same TSH-suppressive effects carry theoretical but unstudied risks. Endocrinologists caring for girls with thyroid conditions would need specific data before considering this drug.

Pediatric Titration: What the Evidence Does (and Does Not) Show

No published pediatric pharmacokinetic study of resmetirom exists as of January 2025. What follows is an evidence-based framework synthesizing the adult PK data, the FDA Pediatric Research Equity Act (PREA) obligations triggered by the adult approval, and the physiological factors most relevant to girls.

FDA PREA Requirements for Resmetirom

Under the Pediatric Research Equity Act, any drug approved for an adult condition that also occurs in pediatric patients must undergo a pediatric study plan submitted to and approved by FDA. Madrigal Pharmaceuticals, the maker of Rezdiffra, submitted an initial Pediatric Study Plan as part of the New Drug Application process. FDA has authority to require those studies as a post-marketing commitment. Specific timelines for completion are not publicly posted as of this writing, but MASH clearly occurs in children, triggering PREA coverage.

What Adult PK Suggests About Pediatric Dosing Logic

Resmetirom is highly protein-bound (greater than 99%) and undergoes extensive hepatic metabolism, primarily via CYP3A4 and CYP2C8. The adult label notes that exposure increases nonlinearly with dose, meaning small dose changes can produce larger-than-expected changes in plasma concentration. For pediatric weight-based dosing, this nonlinearity means a simple mg/kg extrapolation from adult doses may not be safe. Pediatric PK trials typically use allometric scaling, which accounts for the way children's organ sizes, blood flow, and enzyme maturity differ from adults. Girls in Tanner stage II-IV would likely be studied separately from younger children because of the influence of sex steroids on CYP enzyme expression.

Hypothetical Titration Framework (Not a Clinical Protocol)

Given the adult flat-start design, and the general principle in pediatric pharmacology that new drugs in children begin at lower exposures and escalate, a future pediatric titration schedule would likely include:

• A lower starting dose than the adult weight-based threshold, possibly 40-60 mg once daily for adolescents above a defined weight cutoff
• A 4-to-8-week tolerability period at the starting dose before dose escalation, unlike the adult approach
• Safety monitoring at weeks 2, 4, 8, and 12 covering liver enzymes, TSH, thyroid hormones, fasting lipids, and growth parameters
• Weight-based thresholds that differ from the adult 100 kg cutoff, calibrated to pediatric body composition data

This framework reflects standard FDA pediatric drug development logic. It is not a clinical protocol and should not be used as prescribing guidance.

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory for any woman or girl of reproductive potential considering this drug. Read it carefully.

Resmetirom Is Contraindicated in Pregnancy

The FDA label carries a clear contraindication: resmetirom must not be used during pregnancy. Animal reproductive studies showed embryo-fetal toxicity at doses producing exposures below the human therapeutic range. No adequate human pregnancy data exist. Thyroid hormone receptor agonism during fetal development carries theoretical risk to fetal thyroid axis programming, cardiac development, and bone formation.

Any woman of reproductive age prescribed resmetirom must use effective contraception during treatment. The label does not specify a washout period after stopping before pregnancy is considered safe, because human clearance data in this context are limited. Discuss washout timing with your prescribing clinician before stopping contraception.

What This Means for Adolescent Girls Specifically

An adolescent girl prescribed resmetirom off-label who becomes sexually active faces a real teratogenic risk if she is not using reliable contraception. Clinicians prescribing this drug to any post-menarche girl should document contraception counseling and document the contraceptive method in use. This is not optional clinical practice; it is the minimum standard given the animal embryotoxicity data.

Lactation

The FDA label states that there are no data on resmetirom presence in human milk, the effects on the breastfed infant, or effects on milk production. The drug is not recommended during breastfeeding. For a postpartum woman who developed MASH during pregnancy, this means treatment initiation should wait until breastfeeding is discontinued.

Perimenopause and Menopause

Postmenopausal women are at increased risk of MASH because estrogen's hepatoprotective effects on lipid metabolism decline after menopause. If you are postmenopausal and being evaluated for MASH, resmetirom's contraception requirement does not apply, but the interaction between menopausal hormone therapy (MHT) and THR-beta agonism has not been studied in clinical trials. The thyroid effects of resmetirom, specifically TSH suppression, may affect the interpretation of thyroid function tests in women on MHT, since estrogen independently raises thyroid-binding globulin. Discuss this with your endocrinologist.

Who This Drug Is (and Is Not) Right For, By Life Stage

Reproductive Years (Ages 18-40)

Women in this group who have biopsy-confirmed or noninvasive-test-confirmed MASH with stage F2 or F3 fibrosis are the currently approved population. Reliable contraception is non-negotiable. Women with PCOS who have overlapping metabolic liver disease are a particularly logical candidate group, though PCOS itself was not a stratification variable in MAESTRO-NASH.

Trying to Conceive

Resmetirom is contraindicated during pregnancy and has no established washout-to-conception guidance. Women actively trying to conceive should not be on this drug. Discuss whether MASH-directed lifestyle intervention or other options can bridge the gap during a planned conception period.

Postpartum and Lactation

Not appropriate during breastfeeding. Women who had MASH before pregnancy should discuss restarting resmetirom only after weaning is complete.

Perimenopause

If you are 40-52 with irregular cycles, you may still be able to conceive. Contraception requirements apply until menopause is confirmed (12 consecutive months of amenorrhea). TSH monitoring is advisable every 6 months given the hormonal fluctuations of this life stage interacting with resmetirom's thyroid effects.

Post-Menopause

No contraception requirement. Baseline and follow-up thyroid function testing remains advisable. MHT interactions with resmetirom PK have not been formally studied.

Children and Adolescents (<18 years)

Not approved. Not recommended outside of a clinical trial. If your daughter has been diagnosed with MASH and a clinician suggests resmetirom, ask specifically whether a formal pediatric trial is enrolling and whether that is the appropriate route.

Evidence Gaps That Women and Families Must Know About

The clinical trial record for resmetirom has real blind spots.

The MAESTRO-NASH trial enrolled 966 patients at 80 mg, 100 mg, or placebo. The sex breakdown of the trial was not prominently featured in the primary publication. Women are biologically distinct from men in hepatic fat metabolism, partly because estrogen affects hepatic very-low-density lipoprotein (VLDL) secretion and TG clearance. Whether resmetirom's 23.9% MASH resolution rate at 80 mg holds equally across sexes has not been published in a sex-disaggregated subgroup analysis.

Women have historically been underrepresented in NASH/MASH clinical trials, a pattern that shapes the reliability of applying trial results directly to female patients. This is an evidence gap, not a reason to avoid treatment, but it is a reason to ask your clinician what the trial's female-specific outcomes looked like.

Pediatric data, particularly for girls, are entirely absent from the published literature as of this writing. Any statement about appropriate pediatric dosing or safety in children is extrapolation.

Monitoring Schedule for Girls and Women on Resmetirom (Adult Protocol)

The FDA label and clinical practice guidelines from hepatology societies support the following monitoring approach for adult women:

| Timepoint | Tests | |---|---| | Baseline | LFTs (ALT, AST, ALP, bilirubin), TSH, free T4, fasting lipid panel, pregnancy test | | Week 4 | LFTs, TSH, GI tolerability assessment | | Week 12 | LFTs, TSH, free T4, fasting lipids | | Week 24 | LFTs, TSH, lipid panel, noninvasive fibrosis assessment (FibroScan or MRE) | | Week 52 | Full panel, consideration of repeat liver biopsy per trial protocol | | Ongoing (every 6 months) | LFTs, TSH, lipid panel |

For post-menarche adolescents in any future clinical trial, growth parameters, bone age assessment, and menstrual cycle regularity tracking would be added to this list.

A Clinician's Perspective on Pediatric Prescribing Pressure

WomanRx editorial board member Maya Okafor, MD, notes: "Families dealing with a teenage daughter's MASH diagnosis understandably want the same options adults have, especially when lifestyle intervention has reached its limits. The honest answer right now is that we do not have the pharmacokinetic data to dose resmetirom safely in a 14-year-old, and the thyroid effects of this drug in a pubertal girl are genuinely unstudied. Waiting for the pediatric trials is not pessimism. It is the standard we hold ourselves to for any new drug class."

This perspective aligns with FDA guidance. The agency has not granted any pediatric waiver for resmetirom that would allow it to skip pediatric studies, meaning formal data generation is expected and required.

Practical Steps If Your Daughter Has MASH Right Now

If your daughter has been diagnosed with MASH, metabolic-associated fatty liver disease (MAFLD), or a related condition, here is what evidence supports today:

1. Dietary change is the most evidence-backed intervention. A Mediterranean-pattern diet reduces hepatic steatosis in adolescents with NAFLD, with studies showing 10-30% reductions in liver fat by MRI over 6-12 months.
2. Exercise reduces liver fat independent of weight loss. Aerobic exercise 3-5 days per week is a first-line recommendation per AASLD pediatric NAFLD guidelines.
3. PCOS evaluation is warranted in any adolescent girl with MASH. If untreated PCOS is driving insulin resistance and liver fat, addressing PCOS (with metformin or lifestyle modification) may reduce MASH severity before any hepatology-specific drug is needed.
4. Ask about clinical trials. ClinicalTrials.gov lists enrolling studies for pediatric MASH pharmacotherapy. Ask your hepatologist whether your daughter qualifies.
5. Avoid off-label resmetirom. The risk-benefit calculation without pediatric safety data does not favor use outside a trial setting.